SCHEMBL2860583

SCHEMBL2860583

O=C(NCc1ccc2ccccc2c1)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
MCHR1 Q99705 1/20 0.43
MC4R P32245 1/20 0.37
CFD P00746 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MMP13 P45452 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36
P2RX7 Q99572 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
TPSAB1 Q15661 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
TSHR P16473 1/20 0.34
METAP2 P50579 1/20 0.34
METAP1 P53582 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858851 0.90 NPSR1 (0.47) NPSR1MCHR1MC4RALDH1A1P2RX7
SCHEMBL2861757 0.88 NPSR1 (0.47) NPSR1MC4RCFDKDM4EKMT2A
SCHEMBL2856315 0.87 NPSR1 (0.58) NPSR1MC4RMEN1KMT2AALDH1A1
SCHEMBL2870790 0.87 NPSR1 (0.48) NPSR1MC4RMEN1KMT2AALDH1A1
SCHEMBL2871764 0.87 NPSR1 (0.48) NPSR1MC4RMEN1KMT2AALDH1A1
SCHEMBL2865680 0.84 NPSR1 (0.46) NPSR1MC4RKDM4EALDH1A1TSHR
SCHEMBL2863305 0.83 NPSR1 (0.45) NPSR1MC4RALDH1A1TSHR
SCHEMBL2865812 0.82 NPSR1 (0.51) NPSR1MEN1KMT2AALDH1A1P2RX7
SCHEMBL2860998 0.82 NPSR1 (0.41) NPSR1MC4RTSHR
SCHEMBL2868224 0.82 TDP1 (0.43) NPSR1ALDH1A1P2RX7METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 NPSR1 211/4885MCHR1 690/4885MC4R 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.